🎉 M&A multiples are live!
Check it out!

Akero Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Akero Therapeutics and similar public comparables like Julphar, Benevolent AI, and Vivoryon Therapeutics.

Akero Therapeutics Overview

About Akero Therapeutics

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.


Founded

2017

HQ

United States of America
Employees

63

Website

akerotx.com

Financials

LTM Revenue n/a

LTM EBITDA -$303M

EV

$2.3B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Akero Therapeutics Financials

Akero Therapeutics has a last 12-month revenue of n/a and a last 12-month EBITDA of -$303M.

In the most recent fiscal year, Akero Therapeutics achieved revenue of n/a and an EBITDA of -$247M.

Akero Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Akero Therapeutics valuation multiples based on analyst estimates

Akero Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$149M -$247M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$112M -$152M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Akero Therapeutics Stock Performance

As of April 15, 2025, Akero Therapeutics's stock price is $38.

Akero Therapeutics has current market cap of $3.0B, and EV of $2.3B.

See Akero Therapeutics trading valuation data

Akero Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$2.3B $3.0B XXX XXX XXX XXX $-3.91

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Akero Therapeutics Valuation Multiples

As of April 15, 2025, Akero Therapeutics has market cap of $3.0B and EV of $2.3B.

Akero Therapeutics's trades at n/a LTM EV/Revenue multiple, and -7.5x LTM EBITDA.

Analysts estimate Akero Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Akero Therapeutics and 10K+ public comps

Akero Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $2.3B XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA -9.2x XXX XXX XXX
P/E -11.9x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -9.9x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Akero Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Akero Therapeutics Valuation Multiples

Akero Therapeutics's NTM/LTM revenue growth is Infinity%

Akero Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $4.5M for the same period.

Over next 12 months, Akero Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Akero Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Akero Therapeutics and other 10K+ public comps

Akero Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth 66% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $4.5M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Akero Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Akero Therapeutics M&A and Investment Activity

Akero Therapeutics acquired  XXX companies to date.

Last acquisition by Akero Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Akero Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Akero Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Akero Therapeutics

When was Akero Therapeutics founded? Akero Therapeutics was founded in 2017.
Where is Akero Therapeutics headquartered? Akero Therapeutics is headquartered in United States of America.
How many employees does Akero Therapeutics have? As of today, Akero Therapeutics has 63 employees.
Who is the CEO of Akero Therapeutics? Akero Therapeutics's CEO is Dr. Andrew Cheng, M.D.,PhD.
Is Akero Therapeutics publicy listed? Yes, Akero Therapeutics is a public company listed on NAS.
What is the stock symbol of Akero Therapeutics? Akero Therapeutics trades under AKRO ticker.
When did Akero Therapeutics go public? Akero Therapeutics went public in 2019.
Who are competitors of Akero Therapeutics? Similar companies to Akero Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Akero Therapeutics? Akero Therapeutics's current market cap is $3.0B
What is the current EBITDA of Akero Therapeutics? Akero Therapeutics's last 12-month EBITDA is -$303M.
What is the current EV/EBITDA multiple of Akero Therapeutics? Current EBITDA multiple of Akero Therapeutics is -7.5x.
Is Akero Therapeutics profitable? Yes, Akero Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.